CA2324344A1 - Fluorescent assay for topoisomerase inhibitors - Google Patents
Fluorescent assay for topoisomerase inhibitors Download PDFInfo
- Publication number
- CA2324344A1 CA2324344A1 CA002324344A CA2324344A CA2324344A1 CA 2324344 A1 CA2324344 A1 CA 2324344A1 CA 002324344 A CA002324344 A CA 002324344A CA 2324344 A CA2324344 A CA 2324344A CA 2324344 A1 CA2324344 A1 CA 2324344A1
- Authority
- CA
- Canada
- Prior art keywords
- dna
- fluid
- topoisomerase
- test compound
- gyrase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
Abstract
The subject invention involves methods for determining the activity of test compounds as topoisomerase inhibitors comprising mixing, in a fluid, a test compound, a DNA, and a topoisomerase; incubating the fluid; then incorporating a cyanine nucleic acid dye such as PicoGreen, measuring the fluorescence, and comparing to the fluorescence from controls.
Description
Fluorescent Assay for Topoisomerase Inhibitors TECHNICAL FIELD
The subject invention relates to analytical procedures which use fluorescent dyes for detection of and/or for providing a quantitative measure of substances which inhibit tvpoisomerase enzymes, especially those of bacteria.
BACKGROUND OF THE INVENTION
Gyrase, a type II topoisomerase, is an essential bacterial enzyme and inhibition of gyrase by fluoroquinolones, popular commercial antibacterials, disrupts bacterial replication leading to rapid cell death. Among other functions, gyrase mediates bacterial DNA supercoiling which is essential for DNA metabolism and bacterial survival and replication. (See Wang, J. C; "DNA Topoisomerases", Annu. Rev. Biochem., vol.
(1996), pp. 635-692.) Limited success has been achieved in using the activity of topoisomerases on DNA as bases for topoisomerase assays. (See Andrea, J. E.; Adachi, K.; and Morgan, A.
R.; "Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs:
quantitation of catalytic activity and DNA cleavage", Molec. Pharmacol., vol.
40 (I991), pp. 495-501; Lerner, C. G.; Saiki, A. Y. C.; Mackinnon, A. C., and Xuei, X.;
"High throughput screen for inhibitors of bacterial DNA topoisomerase I using the scintillation proximity assay", J. Biomolec. Screening, vol. 1(3) (1996), pp. 119-127; and Sandhu, L.
C.; Warters, R. L.; and Dethlefsen, L. A.; "Fluorescence studies of Hoechst 33342 with supercoiIed and relaxed plasmid pBR322 DNA", Cytometry, vol. 6 (1985), pp. 191-194.) Although gel-based methods to discriminate relaxed and supercoiled DNA are reported in the literature, there is a paucity of information concerning gyrase assays having potential use as automated or high throughput screening assays. (See Barrett, J.
F.; Sutcliffe, J. A.; and Gootz, T. D.; "In vitro assays used to measure the activity of topnisomerases", Antimicrob. Agents Chemother., vol. 34(1) (1990), pp. 1-7.) It is known that fluorescent dyes such as ethidium bromide tend to bind differentially to various DNA topologies, but it provides inconsistent results. (See Foglesong, P. D.;
"Fluoremetric methods employing Iow concentrations of ethidium bromide for DNA
topoisomerase and endonuclease assays", Anal. Biochem., vol. 182 (1989), pp.
284-288;
and Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; and Evans, D. H.;
"Review: ethidium fluorescence assays. Part 1. Physicochemical studies", Nucleic Acids Research, vol. 7(3) (1979), pp. 547-569.) SUMMARY OF THE INVENTION
The subject invention involves methods for determining the activity of test compounds as topoisomerase inhibitors by incubating a DNA with the topoisomerase of interest, both in the presence and absence of the test compound of interest, incorporating a cyanine nucleic acid dye, and comparing the fluorescence from the dye when the test compound is present and absent.
DETAILED DESCRIPTION OF THE INVENTION
Commercial substrate (relaxed DNA) enzyme (gyrase) and buffers are available for performing gyrase-mediated supercoiling of DNA. The identification and application of cyanine nucleic acid dyes, such as PicoGreen~ (available commercially from Molecular Probes, Inc., Eugene, OR), as nucleic acid stains for differentiating DNA topoisomers (e.g., relaxed and supercoiled DNA) represents a key discovery of the subject invention. PicoGreen~ is commonly used to quantitate duplex DNA, but has not been described as a tool to effectively differentiate DNA topoisomers. (See Singer, V.
L.; Jones, L. J.; Yue, S. T.; and Haugland, R. P.; "Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA
quantitation", Analytical Biochem. vol. 249 (1997), pp. 228-238; and Product Information Sheet of Molecular Probes, Inc.: "PicoCrreen~ dsDNA (luantitation Reagent and Kit", 1996.) Since the subject invention assay allows discrimination between topological isomers of duplex DNA, inhibitors (e.g., fluoroquinolones) of topoisomerases (e.g., gyrase) which catalyze the interconversion of DNA topoisomers can be identified by drug-induced changes in DNA topology (e.g., reduction of supercoiling). Dyes such as PicoGreen~ differentially bind to relaxed and supercoiled topological isomers of duplex DNA. Unlike other nucleic acid dyes, they reproducibly fluoresce more intensely upon binding to supercoiled DNA (product) following gyrase-mediated supercoiling of relaxed DNA, allowing greater discrimination between DNA topoisomers than achieved by previous assays. Inhibitors of gyrase are identifiable by reduction in fluorescence compared to control.
The subject invention involves methods for determining activity of test compounds as topoisomerase inhibitors comprising the following steps:
(a} mixing together, in a fluid, the test compound, a DNA, and a topoisomerase;
(b) incubating the fluid from step (a);
(c) incorporating a cyanine nucleic acid dye in the incubated fluid from step (b);
(d) measuring the fluorescence from the dye in the fluid from step (c);
(e) repeating steps (a) to (d) omitting the test compound from the fluid of step (a);
(fj optionally repeating steps (a) to (d) omitting the test compound and the topoisomerase from the fluid of step (a); and (g) comparing the fluorescence measured in steps (d) and (e) or (d), (e) and (f).
In step (a), the liquid components) of the fluid are selected such that the test compound, DNA and topoisomerase are intimately mixed, preferably as a fine suspension, or more preferably in solution. The fluid is preferably aqueous-based, but may be based on another solvent or a solvent mixture, e.g., a water/cosolvent mixture.
Cosolvents mixed with water for this purpose include, e.g., dimethyl sulfoxide (DMSO) and N, N-dimethylformamide (DMF). The fluid is preferably an aqueous solution or an aqueous/cosolvent solution containing up to about 2% cosolvent.
Typically, more than one concentration of the test compound is tested using a subject invention method, to ascertain the range of concentrations, and particularly the lowest level of concentration, of the test compound which might inhibit the topoisomerase enzyme of interest. Preferably from about three to about eight or more different concentrations of the test compound are tested, the ratio of highest concentration to the lowest concentration being from about lOZ to about 105.
The WO 99/49077 PCT/IB99/004?3 concentration of the test compound in the fluid of step (a) is preferably from about 0.1 p,g/ml to about 1000 pg/ml, more preferably from about 1 p.g/ml to about 100 p,g/ml.
The DNA is selected to complement the topoisomerase, in that a DNA that will be changed by interaction with the topoisomerase is needed. For example, gyrase (a type II topoisomerase) facilitates supercoiling of DNA. For interaction with gyrase, a relaxed DNA is preferred. A suitable, commercially-available relaxed DNA is Relaxed Plasmid pBR 322, available from Lucent Ltd., Leicester, U.K.
The concentration of the DNA in the fluid of step (a) is preferably from about 0.1 pg/ml to about 100 pg/ml, more preferably from about 1 ~g/ml to about SO
~,g/ml. The mole ratio of test compound:DNA in the fluid of step (a) is preferably from about 1:10' to about 1:10-3, more preferably from about 1:10-6 to about 1:10-4.
The purpose for employing the subject invention methods is generally to identify compounds which will inhibit the topoisomerase of certain organisms of interest, particularly pathogenic bacteria. Compounds which inhibit bacterial topoisomerase may be lethal to such bacteria. Type I and type II topoisomerases are known, and are useful in the subject invention methods. Gyrase is a preferred type II topoisomerase known to facilitate supercoiling of DNA. Commercially available topoisomerases preferred for use in the subject invention methods include the following: "wild-type"
gyrase, such as that from E. coli available from Lucent Ltd., and "quinolone-resistance gyrase", such as A(Trp)2B2 available from Lucent Ltd.
The fluid of step (a) preferably comprises the topoisomerase at a concentration from about 0.001 ~tg/ml to about 10 p,g/ml, more preferably from about 0.01 pg/ml to about I pg/ml. The fluid of step (a) preferably has a mole ratio of DNAaopoisomerase of from about 10:1 to about 1:100, more preferably from about 1:1 to about 1:10.
In step (b) the fluid from step (a) is incubated to allow the topoisomerase to facilitate changes in the DNA if it is not inhibited from doing so by the test compound.
The incubation is preferably for a period of from about 0.2 hour to about 24 hours, more preferably from about 1 hour to about 6 hours, preferably at a temperature of from about 20°C to about SS°C, more preferably from about 35°C to about 40°C.
In step (c) a cyanine nucleic acid dye is incorporated in the incubated fluid from step (b). Preferred cyanine nucleic acid dyes useful in the subject invention assays are disclosed in U.S. Patent Nos. 5,436,134 and 5,658,751 issued to Haugland et aI. and Yue et al. on July 25, 1995 and August 19, 1997, respectively, both incorporated herein by reference. PicoGreen~ is a highly preferred cyanine nucleic acid dye useful in the subject invention methods.
The dye is added to the incubated fluid from step (b), resulting in a concentration of the dye in the fluid of step (c) of preferably from about 0.01 ~M to about 10 p,M, more preferably from about 0.1 pM to about 1 ~.M. The mole ratio of DNA:dye in the fluid of step (c) is preferably from about 1:1013 to about 1:1017, more preferably from about 1:1014 to about 1:1016.
In step (d), the fluorescence from the dye in the fluid from step (c) is measured using known methods. The wave lengths or excitation and emission is typically unique for each dye, and is readily ascertained without undue experimentation.
Preferred for the cyanine dyes useful in the subject invention method is an excitation of from about 470 nm to about 500 nm, more preferably from about 480 nm to about 490 nm, and an emission preferably from about 510 nm to about 540 nm, more preferably from about 520 nm to about 530 nm.
Examples The following is a non-limiting example of the use of a subject invention assay procedure, using standard 96-well plates useful in performing high throughput screening assays.
On day of assay, compounds to be tested for activity as gyrase inhibitors are prepared at 900 leM in sterile double-distilled water. Using a standard micropipette, 10 p,l of dissolved test compound is placed into individual wells of a 96 well "U" shaped microtitre plate (Dynatech, #011-010-0715) with lid (Dynatech, #001-010-5550).
Column 12 contains negative and positive controls ( 10 p.l of sterile double-distilled water in place of test compound). Next, 10 ~,1 of a master mix containing 6.0 ~I of SX
incubation buffer (35mM Tris HCl (pH 7.5), 24 mM KCI, 4 mM MgCl2, 2 mM
dithiothreitol, 1.8 mM Spermidine, 6.5% glycerol (w/v), 0.1 mg/ml bovine serum albumin), 1.0 pl of 30 mM ATP, 0.25 pg of relaxed DNA (Lucent Limited, UK) is placed into each well. Then, 10 p,l of diluted gyrase (Lucent Limited, UK) in SX storage buffer (50 mM Tris HCl (pH 7.5) 100 mM KCI, 2 mM dithiothreitol, 1 mM EDTA, 50%
glycerol (w/v)) is aliquoted into all wells with the exception of the 4 "relaxed" DNA
controls (Column 12, rows A-D), which receive storage buffer without gyrase.
The 96-well plates are then placed into a 37°C incubator for 3 hours.
After incubation, 70 pl of a 1:400 dilution (TE buffer - 100 M Tris (pH 8.0) and M EDTA - Sigma, # 27H6652) of PicoGreen~ (Molecular Probes, Inc., # P-7581 ) is added to all wells, and fluorescence is measured on a FLUOstar Microplate reader (BMG Inc.) using 485 nm excitation and 525 nm emission wavelengths.
The following results are obtained:
F(S-DNA) = fluorescence measured from wells with supercoiled DNA (to which relaxed DNA and gyrase, but no test compound, are added).
F(R-DNA) = fluorescence measured from wells with relaxed DNA (to which relaxed DNA, but no gyrase or test compound, are added).
F(TC) = fluorescence measured from wells with test compound (to which relaxed DNA, gyrase, and test compound are all added).
The following equation is used to calculate the signal to noise ratio in the absence of test compound:
Difference (between relaxed F(S-DNAI - F(R-DNA) and supercoiled DNA) - 100 x - F(R-DNA) This calculated % Difference should be at least about 30%, or the results from the experiment may not be reliable.
To calculate the degree of gyrase inhibition mediated by a particular test compound, the following equation is used:
Inhibition = 100 x 1 - F(TC) - F(R-DNA) F(S-DNA) - F(R-DNA) For this calculation, F(S-DNA) and F(R-DNA) are each typically averages of fluorescence for about four wells. F(TC) is typically a single reading of fluorescence for each level of test compound tested.
While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the arts that various changes and modifications of the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
The subject invention relates to analytical procedures which use fluorescent dyes for detection of and/or for providing a quantitative measure of substances which inhibit tvpoisomerase enzymes, especially those of bacteria.
BACKGROUND OF THE INVENTION
Gyrase, a type II topoisomerase, is an essential bacterial enzyme and inhibition of gyrase by fluoroquinolones, popular commercial antibacterials, disrupts bacterial replication leading to rapid cell death. Among other functions, gyrase mediates bacterial DNA supercoiling which is essential for DNA metabolism and bacterial survival and replication. (See Wang, J. C; "DNA Topoisomerases", Annu. Rev. Biochem., vol.
(1996), pp. 635-692.) Limited success has been achieved in using the activity of topoisomerases on DNA as bases for topoisomerase assays. (See Andrea, J. E.; Adachi, K.; and Morgan, A.
R.; "Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs:
quantitation of catalytic activity and DNA cleavage", Molec. Pharmacol., vol.
40 (I991), pp. 495-501; Lerner, C. G.; Saiki, A. Y. C.; Mackinnon, A. C., and Xuei, X.;
"High throughput screen for inhibitors of bacterial DNA topoisomerase I using the scintillation proximity assay", J. Biomolec. Screening, vol. 1(3) (1996), pp. 119-127; and Sandhu, L.
C.; Warters, R. L.; and Dethlefsen, L. A.; "Fluorescence studies of Hoechst 33342 with supercoiIed and relaxed plasmid pBR322 DNA", Cytometry, vol. 6 (1985), pp. 191-194.) Although gel-based methods to discriminate relaxed and supercoiled DNA are reported in the literature, there is a paucity of information concerning gyrase assays having potential use as automated or high throughput screening assays. (See Barrett, J.
F.; Sutcliffe, J. A.; and Gootz, T. D.; "In vitro assays used to measure the activity of topnisomerases", Antimicrob. Agents Chemother., vol. 34(1) (1990), pp. 1-7.) It is known that fluorescent dyes such as ethidium bromide tend to bind differentially to various DNA topologies, but it provides inconsistent results. (See Foglesong, P. D.;
"Fluoremetric methods employing Iow concentrations of ethidium bromide for DNA
topoisomerase and endonuclease assays", Anal. Biochem., vol. 182 (1989), pp.
284-288;
and Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; and Evans, D. H.;
"Review: ethidium fluorescence assays. Part 1. Physicochemical studies", Nucleic Acids Research, vol. 7(3) (1979), pp. 547-569.) SUMMARY OF THE INVENTION
The subject invention involves methods for determining the activity of test compounds as topoisomerase inhibitors by incubating a DNA with the topoisomerase of interest, both in the presence and absence of the test compound of interest, incorporating a cyanine nucleic acid dye, and comparing the fluorescence from the dye when the test compound is present and absent.
DETAILED DESCRIPTION OF THE INVENTION
Commercial substrate (relaxed DNA) enzyme (gyrase) and buffers are available for performing gyrase-mediated supercoiling of DNA. The identification and application of cyanine nucleic acid dyes, such as PicoGreen~ (available commercially from Molecular Probes, Inc., Eugene, OR), as nucleic acid stains for differentiating DNA topoisomers (e.g., relaxed and supercoiled DNA) represents a key discovery of the subject invention. PicoGreen~ is commonly used to quantitate duplex DNA, but has not been described as a tool to effectively differentiate DNA topoisomers. (See Singer, V.
L.; Jones, L. J.; Yue, S. T.; and Haugland, R. P.; "Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA
quantitation", Analytical Biochem. vol. 249 (1997), pp. 228-238; and Product Information Sheet of Molecular Probes, Inc.: "PicoCrreen~ dsDNA (luantitation Reagent and Kit", 1996.) Since the subject invention assay allows discrimination between topological isomers of duplex DNA, inhibitors (e.g., fluoroquinolones) of topoisomerases (e.g., gyrase) which catalyze the interconversion of DNA topoisomers can be identified by drug-induced changes in DNA topology (e.g., reduction of supercoiling). Dyes such as PicoGreen~ differentially bind to relaxed and supercoiled topological isomers of duplex DNA. Unlike other nucleic acid dyes, they reproducibly fluoresce more intensely upon binding to supercoiled DNA (product) following gyrase-mediated supercoiling of relaxed DNA, allowing greater discrimination between DNA topoisomers than achieved by previous assays. Inhibitors of gyrase are identifiable by reduction in fluorescence compared to control.
The subject invention involves methods for determining activity of test compounds as topoisomerase inhibitors comprising the following steps:
(a} mixing together, in a fluid, the test compound, a DNA, and a topoisomerase;
(b) incubating the fluid from step (a);
(c) incorporating a cyanine nucleic acid dye in the incubated fluid from step (b);
(d) measuring the fluorescence from the dye in the fluid from step (c);
(e) repeating steps (a) to (d) omitting the test compound from the fluid of step (a);
(fj optionally repeating steps (a) to (d) omitting the test compound and the topoisomerase from the fluid of step (a); and (g) comparing the fluorescence measured in steps (d) and (e) or (d), (e) and (f).
In step (a), the liquid components) of the fluid are selected such that the test compound, DNA and topoisomerase are intimately mixed, preferably as a fine suspension, or more preferably in solution. The fluid is preferably aqueous-based, but may be based on another solvent or a solvent mixture, e.g., a water/cosolvent mixture.
Cosolvents mixed with water for this purpose include, e.g., dimethyl sulfoxide (DMSO) and N, N-dimethylformamide (DMF). The fluid is preferably an aqueous solution or an aqueous/cosolvent solution containing up to about 2% cosolvent.
Typically, more than one concentration of the test compound is tested using a subject invention method, to ascertain the range of concentrations, and particularly the lowest level of concentration, of the test compound which might inhibit the topoisomerase enzyme of interest. Preferably from about three to about eight or more different concentrations of the test compound are tested, the ratio of highest concentration to the lowest concentration being from about lOZ to about 105.
The WO 99/49077 PCT/IB99/004?3 concentration of the test compound in the fluid of step (a) is preferably from about 0.1 p,g/ml to about 1000 pg/ml, more preferably from about 1 p.g/ml to about 100 p,g/ml.
The DNA is selected to complement the topoisomerase, in that a DNA that will be changed by interaction with the topoisomerase is needed. For example, gyrase (a type II topoisomerase) facilitates supercoiling of DNA. For interaction with gyrase, a relaxed DNA is preferred. A suitable, commercially-available relaxed DNA is Relaxed Plasmid pBR 322, available from Lucent Ltd., Leicester, U.K.
The concentration of the DNA in the fluid of step (a) is preferably from about 0.1 pg/ml to about 100 pg/ml, more preferably from about 1 ~g/ml to about SO
~,g/ml. The mole ratio of test compound:DNA in the fluid of step (a) is preferably from about 1:10' to about 1:10-3, more preferably from about 1:10-6 to about 1:10-4.
The purpose for employing the subject invention methods is generally to identify compounds which will inhibit the topoisomerase of certain organisms of interest, particularly pathogenic bacteria. Compounds which inhibit bacterial topoisomerase may be lethal to such bacteria. Type I and type II topoisomerases are known, and are useful in the subject invention methods. Gyrase is a preferred type II topoisomerase known to facilitate supercoiling of DNA. Commercially available topoisomerases preferred for use in the subject invention methods include the following: "wild-type"
gyrase, such as that from E. coli available from Lucent Ltd., and "quinolone-resistance gyrase", such as A(Trp)2B2 available from Lucent Ltd.
The fluid of step (a) preferably comprises the topoisomerase at a concentration from about 0.001 ~tg/ml to about 10 p,g/ml, more preferably from about 0.01 pg/ml to about I pg/ml. The fluid of step (a) preferably has a mole ratio of DNAaopoisomerase of from about 10:1 to about 1:100, more preferably from about 1:1 to about 1:10.
In step (b) the fluid from step (a) is incubated to allow the topoisomerase to facilitate changes in the DNA if it is not inhibited from doing so by the test compound.
The incubation is preferably for a period of from about 0.2 hour to about 24 hours, more preferably from about 1 hour to about 6 hours, preferably at a temperature of from about 20°C to about SS°C, more preferably from about 35°C to about 40°C.
In step (c) a cyanine nucleic acid dye is incorporated in the incubated fluid from step (b). Preferred cyanine nucleic acid dyes useful in the subject invention assays are disclosed in U.S. Patent Nos. 5,436,134 and 5,658,751 issued to Haugland et aI. and Yue et al. on July 25, 1995 and August 19, 1997, respectively, both incorporated herein by reference. PicoGreen~ is a highly preferred cyanine nucleic acid dye useful in the subject invention methods.
The dye is added to the incubated fluid from step (b), resulting in a concentration of the dye in the fluid of step (c) of preferably from about 0.01 ~M to about 10 p,M, more preferably from about 0.1 pM to about 1 ~.M. The mole ratio of DNA:dye in the fluid of step (c) is preferably from about 1:1013 to about 1:1017, more preferably from about 1:1014 to about 1:1016.
In step (d), the fluorescence from the dye in the fluid from step (c) is measured using known methods. The wave lengths or excitation and emission is typically unique for each dye, and is readily ascertained without undue experimentation.
Preferred for the cyanine dyes useful in the subject invention method is an excitation of from about 470 nm to about 500 nm, more preferably from about 480 nm to about 490 nm, and an emission preferably from about 510 nm to about 540 nm, more preferably from about 520 nm to about 530 nm.
Examples The following is a non-limiting example of the use of a subject invention assay procedure, using standard 96-well plates useful in performing high throughput screening assays.
On day of assay, compounds to be tested for activity as gyrase inhibitors are prepared at 900 leM in sterile double-distilled water. Using a standard micropipette, 10 p,l of dissolved test compound is placed into individual wells of a 96 well "U" shaped microtitre plate (Dynatech, #011-010-0715) with lid (Dynatech, #001-010-5550).
Column 12 contains negative and positive controls ( 10 p.l of sterile double-distilled water in place of test compound). Next, 10 ~,1 of a master mix containing 6.0 ~I of SX
incubation buffer (35mM Tris HCl (pH 7.5), 24 mM KCI, 4 mM MgCl2, 2 mM
dithiothreitol, 1.8 mM Spermidine, 6.5% glycerol (w/v), 0.1 mg/ml bovine serum albumin), 1.0 pl of 30 mM ATP, 0.25 pg of relaxed DNA (Lucent Limited, UK) is placed into each well. Then, 10 p,l of diluted gyrase (Lucent Limited, UK) in SX storage buffer (50 mM Tris HCl (pH 7.5) 100 mM KCI, 2 mM dithiothreitol, 1 mM EDTA, 50%
glycerol (w/v)) is aliquoted into all wells with the exception of the 4 "relaxed" DNA
controls (Column 12, rows A-D), which receive storage buffer without gyrase.
The 96-well plates are then placed into a 37°C incubator for 3 hours.
After incubation, 70 pl of a 1:400 dilution (TE buffer - 100 M Tris (pH 8.0) and M EDTA - Sigma, # 27H6652) of PicoGreen~ (Molecular Probes, Inc., # P-7581 ) is added to all wells, and fluorescence is measured on a FLUOstar Microplate reader (BMG Inc.) using 485 nm excitation and 525 nm emission wavelengths.
The following results are obtained:
F(S-DNA) = fluorescence measured from wells with supercoiled DNA (to which relaxed DNA and gyrase, but no test compound, are added).
F(R-DNA) = fluorescence measured from wells with relaxed DNA (to which relaxed DNA, but no gyrase or test compound, are added).
F(TC) = fluorescence measured from wells with test compound (to which relaxed DNA, gyrase, and test compound are all added).
The following equation is used to calculate the signal to noise ratio in the absence of test compound:
Difference (between relaxed F(S-DNAI - F(R-DNA) and supercoiled DNA) - 100 x - F(R-DNA) This calculated % Difference should be at least about 30%, or the results from the experiment may not be reliable.
To calculate the degree of gyrase inhibition mediated by a particular test compound, the following equation is used:
Inhibition = 100 x 1 - F(TC) - F(R-DNA) F(S-DNA) - F(R-DNA) For this calculation, F(S-DNA) and F(R-DNA) are each typically averages of fluorescence for about four wells. F(TC) is typically a single reading of fluorescence for each level of test compound tested.
While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the arts that various changes and modifications of the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
Claims (10)
1. A method for determining activity of a test compound as a topoisomerase inhibitor comprising the following steps:
(a) mixing together in a fluid the test compound, a DNA, and a topoisomerase;
(b) incubating the fluid from step (a);
(c) incorporating PicoGreen R dye in the incubated fluid from step (b);
(d) measuring the fluorescence from the dye in the fluid from step (c);
(e) repeating steps (a) to (d) omitting the test compound from the fluid of step (a);
(f) optionally repeating steps (a) to (d) omitting the test compound and the topoisomerase from the fluid of step (a); and (g) comparing the fluorescence measured in steps (d) and (e) or in steps (d), (e) and (f).
(a) mixing together in a fluid the test compound, a DNA, and a topoisomerase;
(b) incubating the fluid from step (a);
(c) incorporating PicoGreen R dye in the incubated fluid from step (b);
(d) measuring the fluorescence from the dye in the fluid from step (c);
(e) repeating steps (a) to (d) omitting the test compound from the fluid of step (a);
(f) optionally repeating steps (a) to (d) omitting the test compound and the topoisomerase from the fluid of step (a); and (g) comparing the fluorescence measured in steps (d) and (e) or in steps (d), (e) and (f).
2. The method of Claim 1 wherein the DNA is a relaxed DNA, and the topoisomerase induces supercoiling of such DNA in step (e).
3. The method of Claim 1 or 2 wherein, in the fluid of step (a), the concentration of the test compound is from 0.01 µg/ml to 1000 µg/ml, preferably from 1 µg/ml to 100 µg/ml;
the concentration of the DNA is from 0.1 µg/ml to 100 µg/ml, preferably from 1 µg/ml to 50 µg/ml; the concentration of the topoisomerase is from 0.001 µg/ml to 10 µg/ml, preferably from 0.01 µg/ml to 1 µg/ml; and the concentration of the dye in the fluid of step (c) is from 0.01 µM to 10 µM, preferably from 0.1 µM to 1 µM.
the concentration of the DNA is from 0.1 µg/ml to 100 µg/ml, preferably from 1 µg/ml to 50 µg/ml; the concentration of the topoisomerase is from 0.001 µg/ml to 10 µg/ml, preferably from 0.01 µg/ml to 1 µg/ml; and the concentration of the dye in the fluid of step (c) is from 0.01 µM to 10 µM, preferably from 0.1 µM to 1 µM.
4. The method of any of Claims 1-3 wherein the fluid of step (a) is aqueous-based and comprises from 0% to 2% cosolvent.
5. The method of any of Claims 1-4 wherein the fluid of step (b) is incubated at a temperature of from 20°C to 55°C, preferably from 35°C to 40°C, for a period of from 0.2 hr to 24 hr, preferably from 1 hr to 6 hr.
6. The method of any of Claims 1-5 wherein the topoisomerase is a type II
topoisomerase, preferably a gyrase, more perferably a wild-type gyrase or a quinolone-resistant gyrase.
topoisomerase, preferably a gyrase, more perferably a wild-type gyrase or a quinolone-resistant gyrase.
7. The method of any of Claims 1-6 wherein the mole ratio of test compound:DNA
in the fluid of step (a) is from 1:10 -6 to 1:10 -4, the mole ratio of DNA:topoisomerase in the fluid of step (a) is from 1:1 to 1:10, and the mole ratio of DNA:dye in the fluid of step (c) is from 1:10 14 to 1:10 16.
in the fluid of step (a) is from 1:10 -6 to 1:10 -4, the mole ratio of DNA:topoisomerase in the fluid of step (a) is from 1:1 to 1:10, and the mole ratio of DNA:dye in the fluid of step (c) is from 1:10 14 to 1:10 16.
8. The method of any of Claims 1-7 wherein step (f) is used, and preferably steps (a) to (d) are repeated using at least 3 different concentrations of the test compound in the fluid of step (a), with the ratio of the highest concentration to the lowest concentration being at least 100.
9. The method of any of Claims 1-8 wherein the fluorescence is measured using from 480 nm to 490 nm, preferably 485 nm, excitation; and from 520 nm to 530 nm, preferably 525 nm, emission wavelengths.
10. The method of any of Claims 1-9 wherein the DNA is Relaxed Plasmid pBR
322, and the gyrase is A(Trp)2B2 or wild-type from E. coli.
322, and the gyrase is A(Trp)2B2 or wild-type from E. coli.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7926598P | 1998-03-25 | 1998-03-25 | |
| US60/079,265 | 1998-03-25 | ||
| PCT/IB1999/000473 WO1999049077A1 (en) | 1998-03-25 | 1999-03-22 | Fluorescent assay for topoisomerase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2324344A1 true CA2324344A1 (en) | 1999-09-30 |
Family
ID=22149463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002324344A Abandoned CA2324344A1 (en) | 1998-03-25 | 1999-03-22 | Fluorescent assay for topoisomerase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1086242A1 (en) |
| JP (1) | JP2002507433A (en) |
| AU (1) | AU3269999A (en) |
| CA (1) | CA2324344A1 (en) |
| IL (1) | IL138532A0 (en) |
| NO (1) | NO20004753L (en) |
| WO (1) | WO1999049077A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001270098A1 (en) * | 2000-06-22 | 2002-01-02 | San Diego State University Foundation | Recombination modulators and methods for their production and use |
| GB0424953D0 (en) | 2004-11-11 | 2004-12-15 | Plant Bioscience Ltd | Assay |
| WO2010044101A1 (en) * | 2008-10-08 | 2010-04-22 | V. B. Medicare Pvt. Ltd. | Purification and assay for topoisomerases and use of the assay for screening modulators of topoisomerases |
| WO2012109617A2 (en) * | 2011-02-10 | 2012-08-16 | University Of Central Florida Research Foundation, Inc. | Method of assaying dna topoisomerases and dna binding proteins using high throughput screening |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992020813A1 (en) * | 1991-05-17 | 1992-11-26 | Dana Farber Cancer Institute | Assays for factors affecting circularization of dna, assays for factors affecting dna integration, factors, and uses thereof |
| WO1996021156A1 (en) * | 1995-01-04 | 1996-07-11 | Abbott Laboratories | Method for preparing scintillation proximity assay targets |
-
1999
- 1999-03-22 WO PCT/IB1999/000473 patent/WO1999049077A1/en not_active Application Discontinuation
- 1999-03-22 JP JP2000538035A patent/JP2002507433A/en not_active Withdrawn
- 1999-03-22 IL IL13853299A patent/IL138532A0/en unknown
- 1999-03-22 EP EP99942591A patent/EP1086242A1/en not_active Withdrawn
- 1999-03-22 CA CA002324344A patent/CA2324344A1/en not_active Abandoned
- 1999-03-22 AU AU32699/99A patent/AU3269999A/en not_active Abandoned
-
2000
- 2000-09-22 NO NO20004753A patent/NO20004753L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004753D0 (en) | 2000-09-22 |
| IL138532A0 (en) | 2001-10-31 |
| EP1086242A1 (en) | 2001-03-28 |
| AU3269999A (en) | 1999-10-18 |
| WO1999049077A1 (en) | 1999-09-30 |
| JP2002507433A (en) | 2002-03-12 |
| NO20004753L (en) | 2000-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rist et al. | Fluorescent nucleotide base analogs as probes of nucleic acid structure, dynamics and interactions | |
| US5824557A (en) | Method for detecting and quantitating nucleic acid impurities in biochemical preparations | |
| US7576192B2 (en) | Rapid and sensitive assay for the detection and quantification of coregulators of nucleic acid binding factors | |
| US7276337B2 (en) | Compositions and methods for visual ribonuclease detection assays | |
| US10883137B2 (en) | Method to detect activity of a polymerase | |
| US8124343B2 (en) | IRE-1α substrates | |
| US20030224469A1 (en) | Methods and kits for assays utilizing fluorescence polarization | |
| NZ534930A (en) | Methods of detecting and quantifying nucleic acid binding factors and coregulators thereof based upon proximity-based luminescence transfer | |
| US20070122863A1 (en) | Methods and means for the detection of enzyme-catalyzed cleavage and linking reactions | |
| US7439035B1 (en) | Method of identifying or characterizing a compound that modulates ribonuclease H activity | |
| CA2324344A1 (en) | Fluorescent assay for topoisomerase inhibitors | |
| EP1668158B1 (en) | Rna detection and quantitation | |
| EP1581660A2 (en) | Method of detecting dna single strand breaks | |
| Merkel et al. | Oligonucleotide-based assays for integrase activity | |
| Shapiro et al. | A high-throughput fluorescence resonance energy transfer-based assay for DNA ligase | |
| CA2586534A1 (en) | Assay for measuring an enzyme's capability to modify supercoil topology of nucleic acids and modulators | |
| US20230279290A1 (en) | Compositions and methods for assay measurements | |
| WO1996024694A1 (en) | Method and kit for fluorometric analysis of enzymes catalyzing synthesis of nucleic acids | |
| JP4478231B2 (en) | Method for stabilizing bioluminescent reagents | |
| US6589744B2 (en) | Method and kit for identification for nucleic acid modification enzymes and inhibitors thereof | |
| Jahnz et al. | A novel homogenous assay for topoisomerase II action and inhibition | |
| US8182986B1 (en) | Assays for nucleic acid modifying enzymes | |
| WO2002046453A2 (en) | Method and kit for identification of nucleic acid modification enzymes and inhibitors thereof | |
| AU2003205320B8 (en) | A rapid and sensitive assay for the detection and quantification of coregulators of nucleic acid binding factors | |
| CZ308387B6 (en) | Method of determining the activity of an enzyme causing DNA degradation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |